Anti-CD20 Therapies and COVID-19 Severity in Patients With Relapsing–Remitting and Progressive MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
JAMA Netw Open 2023 Jun 01;6(6)e2319766, E Januel, D Hajage, P Labauge, E Maillart, J De Sèze, H Zephir, J Pelletier, L Guilloton, C Bensa, O Heinzlef, O Casez, D Biotti, B Bourre, S Vukusic, A Maurousset, E Berger, D Laplaud, C Lebrun-Frénay, AL Dubessy, P Branger, E Thouvenot, P Clavelou, F Sellal, E Manchon, T Moreau, C Papeix, F Tubach, C LouapreFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.